Indianapolis-based Elevance Health, Inc. (ELV) is one of the largest U.S. health benefits and managed care companies, providing medical, pharmacy, dental, behavioral, and care management services to government-sponsored and commercial members. With a market cap of $70.6 billion, Elevance operates nationally through its Blue Cross Blue Shield–affiliated health plans and its diversified healthcare services platform. Companies worth $10 billion or more are generally described as "large-cap stocks." Elevance ...

Core Insights - Elevance Health, Inc. announced management changes aimed at simplifying decision-making and enhancing execution across its Carelon and Health Benefits divisions [1][5] Group 1: Management Changes - Mark Kaye, the Executive Vice President and Chief Financial Officer, will now oversee Carelon, which includes pharmacy services, behavioral health, value-based care, and care delivery capabilities, crucial for the company's strategy to reduce care costs [2] - Felicia Norwood, Executive Vice President and Chief Health Benefits Officer, will lead the consolidated Health Benefits organization, integrating major Health Benefits businesses and core functions for improved coordination and operational consistency [3] - Peter D. Haytaian will transition from his role as Executive Vice President and President of Carelon effective May 4, 2026, to focus on family commitments, while serving as a Special Advisor until December 31, 2026, to ensure a smooth leadership transition [4] Group 2: Strategic Objectives - The management changes are designed to support disciplined execution and enhance clarity and coordination as the company scales its operations [5] - The consolidation of Health Benefits under a single structure is expected to strengthen coordination and execution, benefiting members and customers [6] Group 3: Company Overview - Elevance Health serves approximately 104 million consumers through a diverse portfolio of medical, pharmacy, behavioral, clinical, home health, and complex care solutions [6]

Core Insights - Elevance Health, Inc. (ELV) has a market capitalization of $76.5 billion and operates as one of the largest managed healthcare and health-insurance companies in the U.S. [1] - The company provides a range of services through its four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other [1] Stock Performance - ELV stock has underperformed compared to the broader market and its healthcare peers, declining 11.4% over the past 52 weeks and 1.7% year-to-date [2] - In comparison, the S&P 500 Index has returned 11.9% over the past year [2] - The stock has also lagged behind the State Street Health Care Select Sector SPDR Fund (XLV), which fell 8.7% over the past 52 weeks [3] Recent Earnings - On January 28, ELV shares increased by 5.9% following the release of Q4 2025 earnings, with operating revenue rising 10% year-over-year to $49.3 billion [4] - Adjusted EPS for the quarter was $3.33, exceeding expectations, driven by premium increases, Medicare Advantage growth, and strong performance in the Carelon services segment [4] - The benefit expense ratio was reported at 93.5%, an increase of 110 basis points from the previous year, attributed to higher medical costs and changes in Medicare Part D [4] Analyst Expectations - For the current year ending in December, analysts project a 15.6% decrease in EPS to $25.57 [5] - The company has met or exceeded analysts' consensus estimates in three of the last four quarters, with one miss [5] - Among 21 analysts covering the stock, the consensus rating is a "Moderate Buy," consisting of 12 "Strong Buy" ratings and nine "Holds" [5] Analyst Ratings Update - The consensus rating has become more bullish compared to two months ago, when there were 11 "Strong Buy" suggestions [7] - On February 2, JPMorgan analyst Lisa Gill raised the price target for Elevance Health to $397 from $394, maintaining an "Overweight" rating [7]

Core Insights - Loblaw Companies Limited announced a transaction involving the sale of President's Choice Bank and affiliated entities to EQB Inc., along with a long-term strategic relationship with EQB [1] - The company has entered into an automatic share purchase plan (ASPP) to facilitate the purchase of EQB Common Shares [2] Group 1: Transaction Details - The ASPP allows Loblaw's broker to purchase up to 1,220,000 EQB Common Shares, including shares acquired prior to the ASPP [2] - The ASPP will terminate once the maximum amount is purchased or upon closing of the transaction, whichever comes first [2] Group 2: Company Overview - Loblaw is Canada's largest retailer, providing a wide range of products and services including grocery, pharmacy, health and beauty, apparel, and financial services [3] - The company operates over 2,800 locations and employs more than 220,000 individuals, making it one of Canada's largest private sector employers [3] Group 3: Company Purpose and Offerings - Loblaw's purpose is to prioritize the needs and well-being of Canadians, facilitating approximately one billion transactions annually [4] - The company offers a diverse range of grocery stores, pharmacies, financial services, and popular consumer brands [4]

Core Insights - UnitedHealth Group Incorporated's (UNH) outlook for 2026 emphasizes cash strength over revenue growth, indicating a focus on efficient asset utilization and internal capital generation [1] - The revenue guidance for UNH is described as easier, suggesting a more manageable growth trajectory [1] - Optum's integrated care, pharmacy, and data platform are highlighted as key components supporting the company's cash strength [1] Financial Performance - The emphasis on cash strength suggests that UNH is prioritizing liquidity and operational efficiency rather than aggressive revenue expansion [1] - The mention of efficient asset use indicates a strategic approach to capital allocation, which may enhance long-term financial stability [1] Strategic Focus - The integrated care and pharmacy services provided by Optum are positioned as critical to maintaining strong cash flow, reflecting a strategic focus on comprehensive healthcare solutions [1]

Group 1 - The Cigna Group is ranked sixth among the best investments during a recession according to a recent compilation [1] - Mizuho analyst Ann Hynes has maintained a Buy rating on Cigna Group (CI) and adjusted the price target to $325 from $307, indicating a positive outlook despite slowing healthcare utilization growth [1] - Cigna Group is a global health services company providing a range of insurance solutions and operates in over 30 countries, focusing on integrated care and pharmacy benefit management [3] Group 2 - Cigna Group is set to release its fourth quarter 2025 financial results on February 5, 2026 [2]

Core Insights - Elevance Health, Inc. is valued at approximately $76.5 billion and aims to improve health outcomes for individuals, families, and communities throughout their healthcare journey [1] - The company serves over 109 million consumers with a comprehensive portfolio that includes medical, pharmacy, behavioral, clinical, home health, and complex care solutions [2] Financial Performance - Elevance Health's total revenue for fiscal 2025 third-quarter increased by 12% year over year to $50.71 billion, surpassing consensus estimates of $49.52 billion [5] - Despite a 30% year-over-year decline in adjusted EPS to $6.03, this figure exceeded expectations of $4.98, indicating strong operational execution [6] Market Expectations - Wall Street analysts predict a nearly 17% year-over-year decline in EPS to $3.19 for the upcoming fiscal 2025 fourth-quarter earnings report [3] - Projections indicate continued pressure on earnings, with fiscal 2025 EPS expected to drop by 9.2% to $30, followed by an 8.6% decline in fiscal 2026 to $27.41 [3] Stock Performance - Elevance Health shares have decreased by 6% over the past year, contrasting with a 16% increase in the S&P 500 Index and a 20.1% rise in the SPDR S&P Health Care Services ETF [4]

Group 1 - Elevance Health will release its fourth quarter and full year 2025 financial results on January 28, 2026, at 6:00 a.m. EST [1] - A conference call to review these results and the company's outlook will take place at 8:30 a.m. EST on the same day [1] - The conference call can be accessed via specific domestic and international numbers, with a replay available from January 28, 2026, until February 27, 2026 [3] Group 2 - Elevance Health serves 109 million consumers through a diverse portfolio of healthcare solutions, including medical, pharmacy, behavioral, clinical, home health, and complex care [2] - The company's purpose is to improve the health of humanity by supporting consumers, families, and communities throughout their healthcare journey [2]

Core Insights - The Cigna Group is valued at a market cap of $80.6 billion and offers a range of health services and insurance solutions, with Q3 earnings announcement scheduled for October 30, 2025 [1] Financial Performance - Analysts expect Cigna to report a profit of $7.70 per share for Q3 2025, reflecting a 2.5% increase from $7.51 per share in the same quarter last year [2] - For the current fiscal year ending in December, Cigna is projected to report a profit of $29.69 per share, an 8.6% increase from $27.33 per share in fiscal 2024, with further growth expected to $32.97 in fiscal 2026 [3] Stock Performance - Cigna's stock has declined 13.4% over the past 52 weeks, underperforming the S&P 500 Index and the Health Care Select Sector SPDR Fund [4] - Despite reporting better-than-expected Q2 results with adjusted revenue of $67.1 billion and adjusted income of $7.20 per share, the stock fell 10.2% post-announcement due to concerns over a 2.1% decline in total customer relationships [5] Analyst Ratings - Wall Street analysts maintain a "Strong Buy" rating for Cigna, with 17 out of 24 analysts recommending "Strong Buy," and a mean price target of $369.90, indicating a potential upside of 22.4% from current levels [6]

Core Insights - Chewy Inc. is recognized as a strong defensive stock, with solid second-quarter results that exceeded sales guidance [1] - The company reported net sales of $3.1 billion, an 8.6% year-over-year increase, and improved gross margins [2] - Active customers grew by 4.5% year-over-year, reaching nearly 21 million, with an increase in share of wallet [3] Financial Performance - Net sales for the second quarter were $3.1 billion, reflecting an 8.6% increase compared to the previous year [2] - Gross margins improved by 90 basis points to 30.4% [2] - Adjusted net income rose by $36.4 million year-over-year to $141 million, resulting in adjusted earnings per share of $0.34, an increase of $0.10 year-over-year [2] Customer Metrics - Chewy's active customer base increased by 4.5% year-over-year, reaching nearly 21 million [3] - The share of wallet (NSPAC) also grew to $591, indicating a stronger customer engagement [3] Company Overview - Chewy Inc. operates as an e-commerce platform specializing in pet products, supplies, and prescription medications [4] - The company offers a diverse range of products, including pet food, toys, and healthcare items, along with services like pharmacy, insurance, and vet telehealth options [4]